Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on‐demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 320-329

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on‐demand with bypass treatment

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 310-319

John Wiley & Sons Inc

Access to resources Recommend Favorite

A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome

By Speakman Mark   Khullar Vik   Mundy Anthony   Odeyemi Isaac   Bolodeoku John  

Current Medical Research and Opinion, Vol. 24, Iss. 8, 2008-08 ,pp. : 2173-2179

Informa Healthcare

Access to resources Recommend Favorite

Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom

By Karnon J.   Tolley K.   Oyee J.   Jewitt K.   Ossa D.   Akehurst R.  

Current Medical Research and Opinion, Vol. 24, Iss. 6, 2008-06 ,pp. : 1609-1621

Informa Healthcare

Access to resources Recommend Favorite

Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes

By Palmer Andrew J.   Dinneen Sean   Gavin James R.   Gray Alastair   Herman William H.   Karter Andrew J.  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 861-872

Informa Healthcare

Access to resources Recommend Favorite